Lucid Diagnostics (LUCD) said Monday it now has until June 16, 2025, to regain compliance with Nasdaq's minimum bid price requirement for continued listing requirements following a 180-day extension.

To regain compliance, Lucid Diagnostics must maintain a closing bid price of at least $1 per share for at least 10 consecutive business days.

The PAVmed (PAVM) subsidiary said it plans to "take all appropriate actions" to regain compliance with Nasdaq's listing rules within the extension period and that its shares will continue trading on the bourse under the "LUCD" ticker.